Sameer A Greenall1,2,3, Mathew McKenzie4,5,6, Ekatarina Seminova7, Olan Dolezal7, Lesley Pearce7, John Bentley7, Mani Kuchibhotla8, Shengnan C Chen2,6, Kerrie L McDonald3,9, Harley I Kornblum10, Raelene Endersby3,8, Timothy E Adams7, Terrance G Johns3,8. 1. Department of Oncology, Monash University and Monash Health, Clayton, Victoria, Australia. 2. Centre for Cancer Research, Hudson Institute of Medical Research, Clayton, Victoria, Australia. 3. Brain Cancer Discovery Collaborative, New South Wales, Australia. 4. School of Life and Environmental Sciences, Deakin University, Geelong, Victoria, Australia. 5. Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Victoria, Australia. 6. Department of Molecular and Translational Science, Monash University, Clayton, Victoria, Australia. 7. CSIRO Manufacturing, Parkville, Victoria, Australia. 8. Cancer Centre, Telethon Kids Institute, Nedlands, Western Australia, Australia. 9. Cure Brain Cancer Biomarkers and Translational Research Group, Prince of Wales Clinical School, University of New South Wales, New South Wales, Australia. 10. The Intellectual and Developmental Disabilities Research Center, University of California, Los Angeles, California, USA.
Abstract
BACKGROUND: Although epidermal growth factor receptor (EGFR) and its truncated, autoactive mutant EGFR variant (v)III are bona fide drivers of tumorigenesis in some gliomas, therapeutic antibodies developed to neutralize this axis have not improved patient survival in a limited number of trials. Previous studies using cells transduced to exogenously express EGFRvIII may have compromised mechanistic studies of anti-EGFR therapeutics. Therefore, we re-assessed the activity of clinical EGFR antibodies in patient-derived gliomaspheres that endogenously express EGFRvIII. METHODS: The antitumor efficacy of antibodies was assessed using in vitro proliferation assays and intracranial orthografts. Receptor activation status, antibody engagement, oncogenic signaling, and mechanism of action after antibody treatment were analyzed by immunoprecipitation and western blotting. Tracking of antibody receptor complexes was conducted using immunofluorescence. RESULTS: The EGFR domain III-targeting antibodies cetuximab, necitumumab, nimotuzumab, and matuzumab did not neutralize EGFRvIII activation. Chimeric monoclonal antibody 806 (ch806) neutralized EGFRvIII, but not wild-type (wt)EGFR activation. Panitumumab was the only antibody that neutralized both EGFRvIII and wtEGFR, leading to reduction of p-S6 signaling and superior in vitro and in vivo antitumor activity. Mechanistically, panitumumab induced recycling of receptor but not degradation as previously described. Panitumumab, via its unique avidity, stably cross-linked EGFRvIII to prevent its activation, while ch806 induced a marked reduction in the active EGFRvIII disulphide-bonded dimer. CONCLUSIONS: We discovered a previously unknown major resistance mechanism in glioma in that most EGFR domain III-targeting antibodies do not neutralize EGFRvIII. The superior in vitro and in vivo antitumor activity of panitumumab supports further clinical testing of this antibody against EGFRvIII-stratified glioma.
BACKGROUND: Although epidermal growth factor receptor (EGFR) and its truncated, autoactive mutant EGFR variant (v)III are bona fide drivers of tumorigenesis in some gliomas, therapeutic antibodies developed to neutralize this axis have not improved patient survival in a limited number of trials. Previous studies using cells transduced to exogenously express EGFRvIII may have compromised mechanistic studies of anti-EGFR therapeutics. Therefore, we re-assessed the activity of clinical EGFR antibodies in patient-derived gliomaspheres that endogenously express EGFRvIII. METHODS: The antitumor efficacy of antibodies was assessed using in vitro proliferation assays and intracranial orthografts. Receptor activation status, antibody engagement, oncogenic signaling, and mechanism of action after antibody treatment were analyzed by immunoprecipitation and western blotting. Tracking of antibody receptor complexes was conducted using immunofluorescence. RESULTS: The EGFR domain III-targeting antibodies cetuximab, necitumumab, nimotuzumab, and matuzumab did not neutralize EGFRvIII activation. Chimeric monoclonal antibody 806 (ch806) neutralized EGFRvIII, but not wild-type (wt)EGFR activation. Panitumumab was the only antibody that neutralized both EGFRvIII and wtEGFR, leading to reduction of p-S6 signaling and superior in vitro and in vivo antitumor activity. Mechanistically, panitumumab induced recycling of receptor but not degradation as previously described. Panitumumab, via its unique avidity, stably cross-linked EGFRvIII to prevent its activation, while ch806 induced a marked reduction in the active EGFRvIII disulphide-bonded dimer. CONCLUSIONS: We discovered a previously unknown major resistance mechanism in glioma in that most EGFR domain III-targeting antibodies do not neutralize EGFRvIII. The superior in vitro and in vivo antitumor activity of panitumumab supports further clinical testing of this antibody against EGFRvIII-stratified glioma.
Authors: Quan Zhou; Johana C M Vega Leonel; Michelle Rai Santoso; Christy Wilson; Nynke S van den Berg; Carmel T Chan; Muna Aryal; Hannes Vogel; Romain Cayrol; Michael J Mandella; Frank Schonig; Guolan Lu; Sanjiv S Gambhir; Michael E Moseley; Eben L Rosenthal; Gerald A Grant Journal: Sci Rep Date: 2021-03-11 Impact factor: 4.379
Authors: Björn Schneider; Doreen William; Nora Lamp; Annette Zimpfer; Christian Henker; Carl Friedrich Classen; Andreas Erbersdobler Journal: Mol Cell Biochem Date: 2022-04-29 Impact factor: 3.842
Authors: Xiaoliang Wang; Li Zhang; Yifu Song; Yang Jiang; Di Zhang; Run Wang; Tianhao Hu; Sheng Han Journal: Oncogene Date: 2021-06-15 Impact factor: 9.867